Stocktoria
Zymeworks Inc. ZYME
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-06-24
Chart by TradingView
5/9
Piotroski F — financial health
-3.24
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M | $26.7M |
| Operating income | -$92.5M | -$137.1M | -$138.1M | $130.5M | -$215.6M |
| Net income | -$81.1M | -$122.7M | -$118.7M | $124.3M | -$211.8M |
| Operating cash flow | -$33.0M | -$110.1M | -$118.3M | $144.1M | -$192.5M |
| Free cash flow | -$34.5M | -$112.0M | -$120.8M | $136.0M | -$204.9M |
| Total assets | $346.5M | $463.1M | $580.9M | $648.7M | $389.1M |
| Total liabilities | $78.0M | $124.3M | $116.1M | $155.8M | $140.0M |
| Shareholders' equity | $268.5M | $338.8M | $464.8M | $493.0M | $249.1M |
| Ratios | |||||
| Operating margin | -87.3% | -179.7% | -181.6% | 31.6% | -808.2% |
| Net margin | -76.6% | -160.8% | -156.1% | 30.1% | -794.0% |
| FCF margin | -32.6% | -146.8% | -158.9% | 33.0% | -767.8% |
| Return on assets | -23.4% | -26.5% | -20.4% | 19.2% | -54.4% |
| Return on equity | -30.2% | -36.2% | -25.5% | 25.2% | -85.0% |
| Current ratio | 5.88 | 3.40 | 7.41 | 5.70 | 4.01 |
| Revenue growth | 38.9% | 0.4% | -81.6% | 1446.0% | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -3.24 (distress)
- Working capital / assets 0.596
- Retained earnings / assets -2.751
- EBIT / assets -0.267
- Equity / liabilities 3.441
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001937653 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.